2000至2015年澳大利亚和新西兰肝硬化危重患者死亡率下降
研究基于澳大利亚和新西兰172个ICU的非择期入院数据,分析2000年1月1日至2015年12月31日肝硬化患者医院死亡率趋势。肝硬化患者占非择期ICU入院的2.2%(17,044/776,873),医院死亡率为32.4%,非肝硬化组为16.9%(p<0.0001)。调整混杂因素后肝硬化对死亡率有独立影响(OR 1.10,95%CI 1.06-1.15),但调整后年死亡率下降幅度在两组间无差异(OR 0.96 [0.95-0.97] vs. 0.96 [0.96-0.96],p=0.67)。
要点
- 肝硬化患者占非择期ICU入院的2.2%,医院死亡率32.4%,非肝硬化组16.9%。
- 调整后肝硬化对死亡率有独立影响,OR为1.10(95%CI 1.06-1.15)。
- 肝硬化患者调整后年死亡率下降与非肝硬化患者无差异(p=0.67)。
核心结论
- 非择期入住ICU的肝硬化患者死亡率随时间显著下降,降幅与非肝硬化患者相当,且主要取决于器官衰竭数量。
- 非肝移植ICU与肝移植中心的结局相似。
研究设计与样本
- 研究为基于澳大利亚和新西兰重症监护学会结局与资源评估成人患者数据库的队列研究,纳入2000年1月1日至2015年12月31日172个ICU的非择期入院患者,包括肝硬化与非肝硬化患者。
- 采用器官衰竭模型和急性生理学评分评估入院时疾病严重程度,主要结局为医院死亡率。
主要发现
- 肝硬化患者占非择期ICU入院的2.2%(17,044/776,873),医院死亡率为32.4%,非肝硬化组为16.9%(p<0.0001)。
- 调整关键混杂因素后,肝硬化对死亡率有独立影响,OR为1.10(95%CI 1.06-1.15)。
- 调整后年死亡率下降在肝硬化与非肝硬化患者间无差异(OR 0.96 [95%CI 0.95-0.97] vs. 0.96 [95%CI 0.96-0.96],p=0.67)。
- 按机械通气(p=0.92)、肝移植中心状态(p=0.27)或脓毒症存在(p=0.09)分层,肝硬化患者调整后死亡率下降无差异。
- 死亡率随器官衰竭数量增加而升高,但肝硬化不影响该关系(p=0.33)。
临床怎么用
- 作者认为数据支持倡导为肝硬化患者提供更好重症监护可及性的建议。
- 非肝移植ICU与肝移植中心对肝硬化患者的结局相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Few studies have described the outcomes of patients with cirrhosis receiving intensive care unit (ICU) admission at a population level. We aimed to describe trends in the mortality of such patients in Australia and New Zealand (ANZ), and to investigate the relationship with associated organ failures. METHODS: We studied patients admitted to 172 ICUs on a non-elective basis, with and without cirrhosis between January 1st 2000 and December 31st 2015, as recorded by the ANZ Intensive Care Society Centre for Outcome and Resource Evaluation Adult Patient Database. We assessed severity of illness on admission using organ failure models and acute physiology scores. The primary outcome was hospital mortality. RESULTS: Patients with cirrhosis accounted for 17,044 of 776,873 non-elective ICU admissions (2.2%). Cirrhosis hospital mortality was 32.4% compared to 16.9% in the non-cirrhotic group (p<0.0001). After adjustment for key confounders, cirrhosis had an independent effect on mortality with an odds ratio (OR) of 1.10 (1.06-1.15). There was no difference in the adjusted annual decline in mortality between patients with or without cirrhosis (OR 0.96 [0.95-0.97] vs. 0.96 [0.96-0.96], p=0.67). No difference was seen in the adjusted decline in mortality of patients with cirrhosis when stratified by mechanical ventilation (p=0.92), liver transplant centre status (p=0.27) or presence of sepsis (p=0.09). Mortality increased with number of organ failures, however, the presence of cirrhosis was not found to affect this relationship (p=0.33). CONCLUSIONS: The mortality of patients with cirrhosis admitted to ICU on a non-elective basis has declined significantly over time, comparable to patients without cirrhosis, and is predominantly governed by the number of organ failures. Outcomes are similar between non-liver transplant ICUs and liver transplant centres. LAY SUMMARY: The outcomes of patients with liver cirrhosis admitted to intensive care units (ICUs) have been previously regarded as poor. We have demonstrated that in Australia and New Zealand, annual in-hospital death rates following ICU admission in this patient group are lower than previously reported, have improved over 16years to 29% and are at a rate similar to patients without cirrhosis. Our data justify recommendations that advocate better access to intensive care for patients with cirrhosis.
引用
- Majumdar A, Bailey M, Kemp WM, et al. Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015. J Hepatol. 2017. PMID: 28802877. doi:10.1016/j.jhep.2017.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。